Date: 2011-06-28
Type of information: Services contract
Compound: chemistry, biology, ADMET/PK and pharmacology services
Company: Argenta (UK - Galapagos's subsidiary) Pulmagen Therapeutics (UK)
Therapeutic area: Respiratory diseases
Type agreement: Services
Action mechanism:
Disease:
Details: Galapagos NV announced that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects. Building on its excellent reputation in respiratory diseases, Argenta will perform chemistry, biology, ADMET/PK and pharmacology services to bring two respiratory projects to pre-clinical status. The deal with Argenta is part of a discovery and development collaboration that Pulmagen has established with Chiesi Farmaceutici S.p.A., a private Italian Group, with focus in respiratory diseases. The purpose of the discovery programs is to identify new compounds with anti-inflammatory potential to be developed for respiratory conditions characterized by a high unmet medical need such as COPD and cystic fibrosis. The terms of the collaboration between Pulmagen and Chiesi are not disclosed.
Financial terms: Under the terms of the agreement, Argenta will be eligible to receive up to £6 million (€7 million) in fee-for-service payments over two years, with the possibility to extend.
Latest news:
